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Abstract
Angiosarcoma is a biologically aggressive vascular malignancy with a high metastatic potential. In the era of targeted
medicine, knowledge of specific molecular tumor characteristics has become more important. Molecular imaging using
targeted ultrasound contrast agents can monitor tumor progression non-invasively. Secreted frizzled related protein 2
(SFRP2) is a tumor endothelial marker expressed in angiosarcoma. We hypothesize that SFRP2-directed imaging could be a
novel approach to imaging the tumor vasculature. To develop an SFRP2 contrast agent, SFRP2 polyclonal antibody was
biotinylated and incubated with streptavidin-coated microbubbles. SVR angiosarcoma cells were injected into nude mice,
and when tumors were established the mice were injected intravenously with the SFRP2 -targeted contrast agent, or a
control streptavidin-coated contrast agent. SFRP2 -targeted contrast agent detected tumor vasculature with significantly
more signal intensity than control contrast agent: the normalized fold-change was 1.660.27 (n = 13, p = 0.0032). The kidney
was largely devoid of echogenicity with no significant difference between the control contrast agent and the SFRP2-
targeted contrast agent demonstrating that the SFRP2-targeted contrast agent was specific to tumor vessels. Plotting
average pixel intensity obtained from SFRP2-targeted contrast agent against tumor volume showed that the average pixel
intensity increased as tumor volume increased. In conclusion, molecularly-targeted imaging of SFRP2 visualizes
angiosarcoma vessels, but not normal vessels, and intensity increases with tumor size. Molecular imaging of SFRP2
expression may provide a rapid, non-invasive method to monitor tumor regression during therapy for angiosarcoma and
other SFRP2 expressing cancers, and contribute to our understanding of the biology of SFRP2 during tumor development
and progression.
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Introduction
Angiosarcoma is a biologically aggressive vascular malignancy
with a high metastatic potential and subsequent mortality [1]. It
originates from endothelial cells of small blood vessels and may
affect a variety of organs, including the retroperitoneum, skeletal
muscle, subcutis, liver, heart and breast. The outcome of
angiosarcoma is poor for those patients in whom aggressive
surgery cannot be considered, and therefore there is a desperate
need for novel therapies to improve survival in patients with this
highly lethal disease. A better understanding of the biology of
angiosarcoma is needed to identify new molecular targets.
The DeMore laboratory has recently discovered a novel
angiogenesis factor involved in angiosarcoma growth. While
conducting genomic profiling of breast tumor vascular cells
obtained by laser capture microdissection, secreted frizzled related
protein 2 (SFRP2) was identified as a gene with 6-fold increased
expression in tumor endothelium as compared to normal vessels
[2]. SFRP2 is a 33 kDa secreted protein involved in the Wnt
signaling pathway, an important pathway in tumor biology [3].
Since angiosarcomas have been reported to represent the signaling
abnormalities of pathogenic angiogenesis [4], we speculated that
SFRP2 would also be expressed in human angiosarcomas, which
we confirmed by immunohistochemistry [5]. SFRP2 acts as a
novel stimulator of angiogenesis in vivo and in vitro by stimulating
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endothelial cell migration, protecting against apoptosis, and is
required for and stimulates angiosarcoma tube formation [5]. We
recently reported the generation of a murine monoclonal antibody
to SFRP2 that inhibits angiosarcoma allograft and breast cancer
xenograft growth in vivo [6]. Thus, SFRP2 is a novel therapeutic
target for angiosarcoma and other tumors.
Although SFRP2 is a secreted protein, it has been demonstrated
to incorporate into the extracellular matrix [7] and localizes to
tumor endothelium [2]. Thus we hypothesized that SFRP2-
directed imaging could be an approach to imaging the tumor
vasculature. Currently, tumor response following drug treatment is
based on measurement of anatomical size changes [8]. However,
the standard response measurement does not provide insight into
changes of molecular characteristics. In the era of targeted
medicine, knowledge of specific molecular tumor characteristics
has become more important. Molecular imaging using targeted
ultrasound contrast agent can monitor tumor progression non-
invasively [9]. The principle behind ultrasonic molecular imaging
is the selective adherence of microbubble contrast agents to
biomarkers expressed on the endothelium [10]. Once the contrast
agents accumulate at the target site, they enhance the pathologic
tissue via increased acoustic backscatter, thus visualizing the
presence of biomarkers associated with disease [11]. This
approach evaluates biological changes at the molecular level
before measurable anatomic changes occur. In this study we report
the development of a new molecular imaging reagent to non-
invasively monitor the progression of angiosarcoma by targeting
SFRP2 in the tumor vasculature. In addition to a potential clinical
imaging application, this technology allows us to further elucidate
the biology of SFRP2 in tumor progression.
Materials and Methods
Cell culture
Murine SVR angiosarcoma cells were obtained from American
Type Culture Collection (ATCCH, Manassas, VA) and cultured in
low-glucose DMEM with 10% fetal bovine serum (FBS) (Sigma-
Aldrich, St. Louis, MO). ATCC provides authenticated cell line
identity, and in addition, SVR angiosarcoma cells were tested
negative by Research Analytic Diagnostic Laboratory (Columbia,
MO) for PCR evaluation for: Ectromelia, EDIM, LCMV, LDEV,
MHV, MNV, MPV, MVM, Mycoplasma sp., Polyoma, PVM,
REO3, Sendai, TMEV GDVII. Cells culture was carried out at
37uC in a humidified 5% CO2-95% room air atmosphere.
Ethics Statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Institutional Animal Care and Use
Committee (IACUC) for the University of North Carolina at
Chapel Hill approved all animal procedures (IACUC ID No. 12-
125.0). Animals were anesthetized with isoflurane prior to tumor
imaging. All efforts were made to minimize suffering.
Size-sorted ultrasound contrast agent
A lipid solution containing an 18:1:1 molar ratio of DSPC,
PEG2000-PE, PEG2000-PE-Biotin was sonicated to produce lipid
encapsulated perfluorobutane micro bubbles as described previ-
ously [12]. Differential centrifugation was used to isolate micro
bubbles with a mean diameter of approximately 3 microns [13].
Micro bubbles were coated with streptavidin (Sigma, St Louis,
S4762) by incubating 16109 micro bubbles with 13 mg of
streptavidin in PBS. Unbound streptavidin was removed by three
sequential washes with PBS and streptavidin-coated micro bubbles
were stored at a concentration .16109 micro bubbles/ml at 4uC
until needed.
Determining concentration and size-distribution of
ultrasound contrast agents
The size distribution and concentration of our various
ultrasound contrast agents were measured using single particle
optical sizing in an Accusizer 780AD (Particle Sizing Systems, Port
Richey, FL). Concentrations were reported in particles per ml and
particle diameters were reported in microns.
SFRP2-targeted UCA
Three polyclonal antibodies (two raised in goat and one in
rabbit) against different epitopes of SFRP2 were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA): sc-7426, sc-13940
and sc-31574. These antibodies were biotinylated using EZ-
LinkTM Sulfo-NHS-LC-Biotinylation Kit catalogue #21435
(Thermo Scientific, Rockford, IL) according to the manufacturer’s
instructions by the Immunology Core Facility at the University of
North Carolina at Chapel Hill. Biotinylated antibodies were
incubated with streptavidin-coated microbubbles and unbound
antibodies were removed by three sequential washes with PBS.
SFRP2-targeted micro bubbles were stored at 4uC at a concen-
tration .16109 micro bubbles/ml until needed.
Non-targeted control ultrasound contrast agent
Biotinylated polyclonal antibodies raised in either rabbit or goat
against chicken IgY were purchased from Bethyl Laboratories
(Montgomery, TX) to serve as a control IgG mixture for the
polyclonal antibodies to SFRP2. The non-targeted control
ultrasound contrast agents were prepared by incubating a (2:1)
mixture of the biotinylated goat to biotinylated rabbit antibodies
with streptavidin-coated contrast agent as described above.
Verifying biotinylation of anti-SFRP2 and anti-chicken IgY
by PAGE
Biotinylated SFRP2 and control antibodies were incubated with
and without streptavidin prior to polyacrylamide gel electropho-
resis (PAGE) through a 10% bis-tris gel (Invitrogen, Carlsbad, CA)
according to manufacturer’s protocol. The gel was stained with
Coomassie Blue R-250 and the staining intensity and electropho-
retic mobility of biotinylated antibodies bound to streptavidin was
compared to that of biotinylated antibodies alone. An increase in
the apparent molecular weight of the antibody in the presence of
streptavidin demonstrated the antibody’s ability to bind to
streptavidin.
Establishment of angiosarcoma allografts in vivo
Six week-old male nude mice were injected s.c. in their right
hind limb with 16106 SVR angiosarcoma cells. Tumors reached
,7 mm in length after one week of growth.
Molecular imaging of SFRP2 expression with SFRP2-
targeted ultrasound contrast agent
All ultrasound B-mode images were collected at 15 MHz using
a 15L8 linear array transducer with a Siemens imaging system
(Acuson Sequoia 512, Mountain View, CA) to provide images for
selecting the region of interest (ROI) in each imaging plane and to
measure tumor volume. CPS mode, a nondestructive contrast-
specific imaging technique operating at 7 MHz (mechanical
index = 0.18, CPS gain = 23 dB) was used to image targeted
and control UCAs.
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Molecular imaging of SFRP2 expression was performed with
our SFRP2-targeted contrast agent as described previously [14].
Briefly, a 3-dimensional (3D) scan of the angiosarcoma tumor was
performed in B-mode to record the outline of the tumor. 56106
non-targeted streptavidin-coated micro bubbles in approximately
50 ml of saline were injected into the tail vein of nude mice with
angiosarcoma tumors. The perfusion of the tumor and surround-
ing tissue by contrast agents was captured in Cadence mode.
Approximately 18 minutes were required for all free-flowing
contrast agents to clear from the vasculature. At this point a 3D
scan of the tumor and surrounding tissue was recorded in Cadence
mode to capture signal from UCA that remained within the
tumor. A baseline 3D scan was acquired after destroying contrast
agents retained within the tumor with a high-energy D color scan.
SFRP2-targeted micro bubbles (56106 micro bubbles in ,50 ml of
saline) were used in an identical manner to determine the
expression of SFRP2 within the angiosarcoma tumors.
Immunohistochemistry
Tumors were fixed in paraffin, sectioned, and immunohisto-
chemistry was performed as previously described [15] using
SFRP2 (1:200 dilution) as the primary antibody. Control tumor
sections were processed similarly, but without the primary
antibody.
Statistics
Results were expressed as a control-normalized, fold-increase of
baseline-subtracted average volumetric pixel intensity 6 SEM. A
two-tailed, paired t-test was used to compare SFRP2-targeted to
control-targeted imaging. A two-tailed, unpaired t-test was used to
compare control-targeted imaging performed in independent
experiments. To determine if there was a statistically significant
relationship between tumor volume and SFRP2-targeted imaging
signal the Pearson correlation coefficient (r) and its p-value were
calculated. All statistical analyses were performed and all plots
were created using GraphPad Prism version 5.0 d for Mac OS X,
GraphPad Software, San Diego California USA, (www.graphpad.
com).
Results
Verifying Biotinylation of polyclonal anti-SFRP2 and anti-
chicken IgY
To verify successful biotinylation of SFRP2 and control
antibodies, PAGE analyses were performed under non-reducing
conditions because the anti-chicken IgY antibody mixtures
contained a carrier protein with an apparent molecular weight
of ,50 kDa which hindered observation of the reduced heavy
chain. Under non-reducing conditions the ,150 kDa antibody
was clearly present in the absence of streptavidin and shifted to a
higher apparent molecular weight after incubation with strepta-
vidin. Likewise, the apparent molecular weight of the biotinylated
SFRP2 antibody was increased in the presence of streptavidin,
verifying its ability to bind to streptavidin-coated contrast agent.
Size distribution of SFRP2-targeted Ultrasound Contrast
Agent
The size distribution of microbubbles in targeted or non-
targeted contrast agent did not change after addition of
streptavidin and biotinylated antibodies. The average diameter
of the targeted and non-targeted microbubbles was ,3 mm with a
mode of ,4 mm and a median diameter of between ,3–4 mm.
The histogram in Fig. 1 shows the distribution of diameters in a
preparation of SFRP2-targeted contrast agent and is representa-
tive of both the targeted and control contrast agent preparations.
Size parameters for targeted and non-targeted contrast agents used
in this study are presented in Table 1.
SFRP2-targeted contrast agent detected SFRP2
expression in SVR tumor allografts
SFRP2 -targeted contrast agent detected tumor vasculature with
significantly more signal intensity than control streptavidin-coated
contrast agent (Fig. 2): the normalized fold-change was 1.660.27
(n = 13, p = 0.0032). After allowing all freely flowing contrast agent
to be cleared from the circulation, our targeted contrast agent was
retained only in the vasculature within the borders of the allograft,
surrounding tissue had no significant echogenicity.
To serve as a control IgG mixture for the polyclonal antibodies
to SFRP2, in a separate experiment we compared the control
streptavidin-coated contrast agent to an immunoglobulin control
streptavidin-contrast agent. We evaluated the retention of control
streptavidin-coated contrast agent coated with a 2:1 mixture of
Figure 1. Size distribution of ultrasound microbubble contrast
agent bound to SFRP2 antibody via a streptavidin bridge.
Microbubble contrast agent containing biotinylated lipid was size-
sorted by differential centrifugation, prior to sequential incubations
with streptavidin and the SFRP2 antibody mixture. Aliquots of the
contrast agent were used to determine the microbubble concentration
and size distribution (Table 1).
doi:10.1371/journal.pone.0086642.g001
Table 1. Size-distribution of targeted and control contrast
agent diameters (mm).
Contrast agent Mean Stdev Mode Median
SFRP2-targeted 3.6 1.4 4.0 3.8
anti-chicken IgY control 2.9 1.2 3.9 3.0
Streptavidin control 3.5 1.6 4.2 3.7
doi:10.1371/journal.pone.0086642.t001
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biotinylated goat anti-chicken IgY and biotinylated rabbit anti-
chicken IgY. We compared the baseline-subtracted average pixel
intensity of control streptavidin-coated contrast agent to anti-
chicken IgY-contrast agent using an unpaired, two-tailed t-test.
The anti-chicken IgY-contrast agent was retained within the
tumor vasculature at significantly lower levels than the streptavi-
din-coated contrast agent (p = 0.0002, Fig. 3). The anti-chicken
IgY-contrast agent had an average pixel intensity 5-fold lower than
the streptavidin-coated contrast agent. This demonstrates that
immunoglobulin is not responsible for the retention of the SFRP2
contrast agent in the vasculature. Accordingly, we calculated that
the SFRP2-targeted contrast agent would have average baseline-
corrected pixel intensity 8-times higher than the control anti-
chicken IgY-contrast agent.
Immunohistochemistry shows SFRP2 present in SVR
angiosarcoma
To demonstrate that the SVR angiosarcoma expresses SFRP2,
formalin-fixed tumors were stained with a polyclonal antibody to
SFRP2. This verifies that SFRP2 localizes to vessels within the
angiosarcoma (Fig. 2).
SFRP2 – targeted contrast agent is specific for tumor
vasculature
The signal from control streptavidin-coated contrast agent and
SFRP2-targeted contrast was apparent throughout the tumor and
surrounding normal tissue while these reagents were freely
circulating through the vasculature. After allowing all freely
flowing contrast agent to be removed from circulation, video signal
was significantly lower in the normal tissue surrounding the tumor
than within the tumor (Fig. 4a). This demonstrated that the
SFRP2-targeted contrast agent and the control contrast agent did
not bind significantly within normal vasculature. Therefore, the
SFRP2-targeted contrast agent is specific for tumor vessels
compared to normal vessels.
In addition, we examined the video intensity in the kidney and
in the liver (Fig. 4b). We found that both the SFRP2-targed
contrast agent and the control contrast agent were retained within
the liver, resulting in intense echogenicity. On the other hand,
kidney was largely devoid of echogenicity with no significant
difference between the control contrast agent and the SFRP2-
contrast agent, again demonstrating specificity for tumor vessels.
SFRP2 -targeted contrast agent intensity increases with
tumor volume
When we plotted average pixel intensity obtained from SFRP2-
targeted contrast agent against tumor volume (Fig. 5), we found
that in general, average pixel intensity increased as tumor volume
increased (n = 13). Only one of thirteen animals examined had
higher average pixel intensity for the control-contrast agent than
for the SFRP2 -targeted contrast agent (indicated by the arrow in
Fig. 5). Correlation analysis showed a highly significant relation-
ship (p = 0.003, Pearson r = 0.78) between tumor volume and
SFRP2-targeted video signal when omitting the aforementioned
‘‘outlier.’’ Even when this data point was included in the
correlation analysis, there was a significant relationship between
tumor volume and SFRP2- targeted video signal (p = 0.048,
Pearson r = 0.56) as illustrated by the best-fit line in Fig. 5. In the
range of tumor volumes investigated, as tumors increased in
volume SFRP2 expression increased.
Figure 2. SFRP2 -targeted microbubbles bound specifically to
vasculature within angiosarcoma. B-mode images of the SVR
angiosarcoma tumors were overlaid in green with molecular images of
(A) control streptavidin loaded microbubbles or (B) SFRP2 -targeted
microbubbles after three-dimensional molecular imaging. The average
pixel intensity observed for SFRP2 -targeted imaging was significantly
higher (*p = 0.003, n = 13, paired t-test, two-tailed) than observed for
the streptavidin control (C). Immunohistochemistry demonstrated high
levels of expression for SFRP2 in angiosarcoma (D). Black scale bars in
panels A and B represent 1 mm. Black scale bars in panels D and E
represent 35 mm.
doi:10.1371/journal.pone.0086642.g002
Figure 3. Microbubbles targeted with anti-chicken IgY were
retained within angiosarcoma vasculature at significantly
lower levels than microbubbles loaded with streptavidin.
Streptavidin-coated microbubbles were bound to a mixture of
biotinylated anti-chicken IgY (raised in rabbit and goat) to produce
anti-chicken IgY control microbubbles. Three-dimensional molecular
imaging with the anti-chicken IgY control microbubbles resulted in
significantly lower average pixel intensity (*p = 0.0002, n = 10, unpaired
t-test, two-tailed) than observed with microbubbles coated only with
streptavidin.
doi:10.1371/journal.pone.0086642.g003
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Discussion
SFRP2 is a tumor endothelial marker with increased expression
in tumor vessels compared to normal vessels [2], and is expressed
in a wide variety of human tumors including angiosarcoma. We
created an SFRP2 targeted ultrasound contrast agent that is
retained in tumor vasculature but does not bind to normal vessels.
This novel contrast agent could be useful to help differentiate
between benign and malignant lesions on ultrasound, increasing
the specificity of ultrasound for cancer detection.
The molecular imaging of SFRP2 provides a tool to understand
the role of this secreted factor during tumor progression. There
has been controversy in the literature as to whether SFRP2 is a
tumor suppressor or promoter of tumor growth. SFRP2 has been
implicated in binding to Wnts, thereby blocking Wnt binding to
Frizzled receptors, and resulting in inhibition of b-catenin
activation [16]. This, in combination with data showing that
SFRP2 is hypermethylated in certain tumors [17–19]has led to an
assumption that SFRP2 is a tumor suppressor. However, there is a
discrepancy in which several studies have shown that SFRP2 is an
agonist (rather than an antagonist) of b-catenin [20–24] suggesting
the reverse: that SFRP2 may promote tumor growth. Further
evidence to support this theory is that SFRP2 has been found to be
produced by the majority of malignant glioma cell lines, and
SFRP2 overexpressing intracranial glioma xenografts were signif-
icantly larger than xenografts consisting of control cells in nude
mice [25]. Transient transfection of SFRP2 in renal cell carcinoma
has been shown to increase tumor growth in vivo [26]. We recently
reported the development of a murine monoclonal antibody to
SFFRP2 that inhibits the growth of both SVR angiosarcoma and
triple negative breast cancer in vivo.
Through our assumption that the anti-SFRP2 molecularly
targeted contrast agents bind to endothelium in proportion to the
amount of SFRP2 expressed, we hypothesize that we can detect
whether SFRP2 expression increases or decreases during tumor
growth. An increase in SFRP2 as tumor volumes increase would
support the theory that SFRP2 stimulates tumor growth; and a
decrease in SFRP2 while tumors grow would support the theory
that SFRP2 is a tumor suppressor. Our data show that SFRP2
expression increased as tumor volume increased in vivo, providing
further support for the role of SFRP2 as a stimulator of tumor
growth.
Figure 4. Modified microbubble contrast agents were not retained at significant levels in nonmalignant vasculature. B-mode images
(black and white) are shown overlaid with CPS-mode images (green). CPS-mode is sensitive to ultrasound signal typically produced by microbubbles
oscillating within an ultrasound field. (A) In the absence of ultrasound contrast agent (no contrast) there was no CPS-mode signal within the region of
interest (dotted rectangle) outside of the tumor margins. Tissue artifacts generated the CPS-mode signal observed in the absence of contrast agent.
Contrast agent freely flowing through both tumor and non-tumor vasculature generated CPS-mode signal throughout the field of view (panel A,
perfusion, middle frames) with either streptavidin-coated (control, upper frames) or SFRP2- targeted ultrasound contrast agent (lower frames). No
signal remained within the region of interest drawn outside of the tumor margins after allowing all freely flowing contrast agent to be cleared from
the vasculature, while SFRP2 specific signal was retained within the tumor margins. (B) Modified microbubble contrast agents were not retained
within kidney vasculature. Freely flowing streptavidin-loaded microbubbles (panel B, control, upper frames) or SFRP2 - targeted microbubbles (panel
B, lower frames) were allowed to clear from the vasculature prior to three-dimensional molecular imaging. Single frames are shown from two
different animals (animal 1 or animal 2). The dotted oval region of interest represents the location of the kidney (K) and there was no significant
difference in average pixel intensity after injection of either streptavidin-loaded or SFRP2 -targeted microbubbles. In contrast, the liver (L) retained
both modified microbubble contrast agents to a high degree. White scale bars in panels A and B represent 5 mm.
doi:10.1371/journal.pone.0086642.g004
Figure 5. Video intensity from SFRP2 -targeted microbubble
contrast agent correlated significantly with SVR angiosarcoma
tumor volume. The baseline-subtracted average pixel intensity for
each tumor was plotted against tumor volumes determined using our
three-dimensional B-mode scans. Only 1 of 13 animals was observed to
have higher signal for the streptavidin control than for the SFRP2 -
targeted microbubbles (indicated by arrow). Correlation analysis
showed a significant positive relationship between SFRP2 video signal
and tumor volume as both increased together whether analyzed with
(p = 0.048, Pearson r = 0.56) or without (p = 0.003, Pearson r = 0.78) the
single ‘‘outlier’’ animal. Linear regression was used to determine the
best-fit line through all data points to represent this relationship.
doi:10.1371/journal.pone.0086642.g005
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Challenges to anti-tumor and anti-angiogenic compound
development and clinical implementation [27] include lack of
knowledge of early response to therapy and resistance that can
develop to therapy [28]. Molecular imaging of SFRP2 expression
may provide a rapid, non-invasive method to monitor tumor
regression during therapy for angiosarcoma, and contributes to
our understanding of the biology of SFRP2 during tumor
progression.
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